{'fraction_non_alphanumeric': 0.03653846153846154, 'fraction_numerical': 0.0038461538461538464, 'mean_word_length': 6.236111111111111, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

Insulin degludec (IDeg) is a new‐generation, ultra‐long‐acting basal insulin that forms soluble multihexamers upon subcutaneous injection, resulting in a depot from which IDeg is absorbed slowly and continuously into circulation. This double‐blind, two‐period, incomplete block cross‐over trial investigated the pharmacodynamic and pharmacokinetic properties of IDeg at steady state (SS) in people with type 2 diabetes.